Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > New week, day, month, post, threads

<< Previous

Bullboard Posts

Next >>

Comment by JohnnyYegon Apr 01, 2024 4:13pm

113 Views

Post# 35963603

RE:RE:RE:New week, day, month, post, threads

I'm trying to buddy. One thing that frustrates me are the start of the year reports from EY, etc., that state this is the year Big Pharma is focusing on mid size bolt on acquisitions of the 10+ billion dollar range. Exact same predictions for the past 4 or 5 years. I mean geez - change more than the year for each year's report!

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023